StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Lokelma (sodium zirconium cyclosilicate) by Year

Lokelma (sodium zirconium cyclosilicate) — Europe YoY CER (%) (%)

AstraZeneca Lokelma (sodium zirconium cyclosilicate): 34.0% in FY2025, down 24.0 pts from a year earlier.

Latest, FY2025
34.0%
Period ended Dec 31, 2025
Change on a year earlier
-24.0 pts
58.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Lokelma | 698 | 29 | 28 | 301 | 18 | 129 | 50 | 52 | 129 | 39 | 34 | 139 | 29 | 28”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLokelma (sodium zirconium cyclosilicate) — Europe YoY CER (%) (%)Year on yearSource
FY2025Dec 31, 202534.0%-24.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
FY2024Dec 31, 202458.0%-33.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
FY2023Dec 31, 202391.0%–Form 6-K FY2023Q4 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Lokelma (sodium zirconium cyclosilicate) (%), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-lokelma-eu-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?